AMARIN CORP PLC\UK Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
AMARIN CORP PLC\UK (AMRN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.23 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.23M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $12.45M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.93M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.62M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $4.23M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $12.45M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $9.93M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $11.62M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $8.56M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $7.57M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $7.11M 10-K · filed 2021-02-25 | |
| 2018-12-31 | $8.11M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $12.45M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $16.89M 10-K · filed 2018-02-27 | $23.73M 10-K · filed 2017-03-01 |
| 2015-12-31 | $17.98M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $15.60M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $11.66M 10-K · filed 2015-03-03 | |
| 2012-12-31 | $9.15M 10-K · filed 2014-02-27 | |
| 2011-12-31 | $5.71M 10-K · filed 2013-02-28 | |
| 2010-12-31 | $3.00M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |